Endpoints News 生物医药· Kyle LaHucik·· 2026-10-08AI 评分26
Ultragenyx 以 2.1 亿美元出售 PRV 并保留一项待变现
Ultragenyx sells PRV for $210M and still has another to monetize
AI 导读
Ultragenyx Pharmaceutical 正在以 2.1 亿美元的价格向未披露的买家出售一张优先审评券(PRV),这是其最丰厚的销售之一。该公司目前仍持有另一张 PRV 可供变现。
正文
Ultragenyx Pharmaceutical is selling a priority review voucher to an undisclosed buyer for $210 million, marking one of the richest sales …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news